GSK3B and Parkinson disease: Most of the recent research work has demonstrated that there is a connection between neuroinflammation and neurodegenerative disorders, and H3 receptor antagonists demonstrated a favorable impact by reducing the inflammatory biomarkers, suggesting the potential role of these antagonists to concurrently regulate vital brain neurotransmissions and influence numerous signaling pathways related to the development of AD and PD, such as the PI3K/AKT/GSK-3β pathway [217].